Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 9/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 5/20 | 0.43 |
| ▸ | HTR1A | P08908 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7869725 | 1.00 | CCR5 (0.56) | CCR5MEN1KMT2ADRD2HTR1A | |
| SCHEMBL7874879 | 0.91 | CCR5 (0.55) | CCR5MEN1KMT2ASLC18A3SIGMAR1 | |
| SCHEMBL7872008 | 0.91 | CCR5 (0.55) | CCR5MEN1KMT2ASLC18A3SIGMAR1 | |
| SCHEMBL7872009 | 0.91 | CCR5 (0.55) | CCR5MEN1KMT2ASLC18A3SIGMAR1 | |
| SCHEMBL7868460 | 0.91 | CCR5 (0.67) | CCR5SLC18A3SIGMAR1 | |
| SCHEMBL7863366 | 0.91 | CCR5 (0.67) | CCR5SLC18A3SIGMAR1 | |
| SCHEMBL7871208 | 0.91 | CCR5 (0.55) | CCR5MEN1KMT2ASLC18A3SIGMAR1 | |
| SCHEMBL7871214 | 0.91 | CCR5 (0.55) | CCR5MEN1KMT2ASLC18A3SIGMAR1 | |
| SCHEMBL7863251 | 0.90 | CCR5 (0.64) | CCR5MEN1KMT2ADRD2DRD4 | |
| SCHEMBL7863249 | 0.90 | CCR5 (0.64) | CCR5MEN1KMT2ADRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6303593-B1 | FOR THERAPY HUMAN IMMUNODEFICIENCY VIRUS INFECTION, AQUIRED IMMUNODEFICIENCY SYNDROME (AIDS), INFLAMMATORY AND IMMUNOREGULATORY DISORDER OR DISEASE, ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS | MERCK & CO., INC. | 2001-10-16 | — | — | US | claimed |
| US-6303593-B1 | FOR THERAPY HUMAN IMMUNODEFICIENCY VIRUS INFECTION, AQUIRED IMMUNODEFICIENCY SYNDROME (AIDS), INFLAMMATORY AND IMMUNOREGULATORY DISORDER OR DISEASE, ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS | MERCK & CO., INC. | 2001-10-16 | — | — | US | disclosed |